Nucana Plc ADR (NCNA) Stock Price, Quote & News

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 13 1357 1111

Website: www.nucana.com

Address:

3 Lochside Way, Edinburgh, United Kingdom

ScanStock Jul. 21 at 6:21 PM

Insane run starting on ticker MLEC now! Are the low float mafia squeezing MLEC for 300% next?! Bulls shifting to MLEC. Wont be shocked to see a parabolic run 🚀🚀 $NCNA $ELAB $VCIG +

0 · Reply

bills7765 Jul. 21 at 5:01 PM

$NCNA bought 3 shares at 1.28. This is what I been doing whenever it goes down. A lot of daily buys. Makes more sense to do it this way to me.

1 · Reply

bills7765 Jul. 21 at 12:34 PM

$NCNA institutions are rarely able to buy this low of market cap due to their risk metrics. Prolly why they sold few months back as well. Earnings in Aug. Most likely wont hear anything until then. Whole market feels off though. Small caps take big hits when money is tight. If you have the guts, its also best time to buy. I have no timeline. This account goes boom or bust. Not selling for loss. I'll hold til end of time while buying few here and there.

2 · Reply

ChickenClaw Jul. 20 at 5:10 PM

$NCNA 30,000 Shares Makes It Go Up...Only 100 Shares Makes It Drop Back Down....HMMMMM

0 · Reply

ChickenClaw Jul. 20 at 5:08 PM

$NCNA Why Is This Such A Bad Stock But It Keeps Getting Large Blocks Being Bought Up?

1 · Reply

GI812 Jul. 17 at 4:59 PM

$NCNA I bought in on the early morning dip. Lowers my average and helps when we moon.

1 · Reply

ChickenClaw Jul. 17 at 2:57 PM

$NCNA

0 · Reply

Xmarketsthestock Jul. 17 at 1:44 PM

$NCNA

0 · Reply

JamoTries2Trade Jul. 17 at 8:11 AM

$NCNA scam. All bio stocks are scams. Get it through your f’ing heads already

1 · Reply

TVanda00 Jul. 15 at 8:08 PM

$NCNA Keep coming back around to…..BULLISH.

0 · Reply

NuCana appoints Ian Webster as CFO

Jun 1, 2026, 8:00 AM EDT - 7 weeks ago

NuCana Appoints Ian Webster as Chief Financial Officer

May 14, 2026, 4:01 PM EDT - 2 months ago

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

Mar 19, 2026, 4:01 PM EDT - 4 months ago

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

2026-01-06T13:16:19.000Z - 7 months ago

NuCana appoints Bruce as COO

Jan 6, 2026, 8:00 AM EST - 7 months ago

NuCana Appoints Theresa Bruce as Chief Operating Officer

2025-12-10T13:15:35.000Z - 7 months ago

NuCana presents latest clinical data at ESMO 2025 on NUC-7738

2025-12-10T13:05:39.000Z - 7 months ago

NuCana presents data at ESMO on NUC-7738

Dec 10, 2025, 8:00 AM EST - 7 months ago

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Nov 13, 2025, 4:01 PM EST - 8 months ago

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-11-05T13:15:29.000Z - 9 months ago

NuCana announces grant of composition-of-matter patent for NUC-7738 in China

Nov 5, 2025, 8:00 AM EST - 9 months ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

2025-10-19T21:10:12.000Z - 9 months ago

NuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitors

2025-10-14T12:16:01.000Z - 10 months ago

NuCana announces publication of new data for NUC-3373

2025-09-05T12:10:43.000Z - 11 months ago

NuCana compliant with all Nasdaq continued listing criteria

Sep 5, 2025, 8:00 AM EDT - 11 months ago

NuCana Compliant with All Nasdaq Continued Listing Criteria

Sep 3, 2025, 8:00 AM EDT - 11 months ago

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Aug 20, 2025, 4:05 PM EDT - 11 months ago

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-08-08T23:50:31.000Z - 1 year ago

NuCana PLC (ADR) trading halted, news pending

2025-08-01T20:10:41.000Z - 1 year ago

NuCana announces ADS ratio change

Aug 1, 2025, 4:05 PM EDT - 1 year ago

NuCana Announces ADS Ratio Change

2025-07-21T12:28:02.000Z - 1 year ago

NuCana cancels all outstanding Series A Warrants

Jul 21, 2025, 8:05 AM EDT - 1 year ago

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jul 11, 2025, 10:30 AM EDT - 1 year ago

NuCana Announces Plan to Implement ADS Ratio Change

Jun 2, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

2025-05-06T12:42:54.000Z - 1 year ago

NuCana prices 10.8M ADSs at 64.54c in registered direct offering

2025-04-24T10:21:56.000Z - 1 year ago

NuCana files to sell 16.05M American Depositary Shares

2025-03-20T20:55:23.000Z - 1 year ago

NuCana reports Q4 loss per share GBP (0.01) vs GBP (.14)

2025-03-20T20:20:12.000Z - 1 year ago

NuCana Reports Q4 EPS GBP (1) vs. GBP (14)

Mar 20, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 10, 2025, 7:00 AM EST - 1 year ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

2024-11-25T12:05:13.000Z - 1 year ago

NuCana reports Q3 EPS (GBP 0.07) vs (GBP 0.13) last year

Nov 25, 2024, 7:00 AM EST - 1 year ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

2024-11-11T12:12:48.000Z - 1 year ago

NuCana announces initial data from Phase 1b/2 modular study of NUC-3373

Nov 11, 2024, 7:00 AM EST - 1 year ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Oct 4, 2024, 12:03 PM EDT - 1 year ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Sep 25, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

$NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024$

Sep 14, 2024, 3:01 AM EDT - 2 years ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Aug 29, 2024, 4:01 PM EDT - 2 years ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 15, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

May 30, 2024, 8:36 AM EDT - 2 years ago

NuCana to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 8:00 AM EDT - 2 years ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 16, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024, 4:01 PM EDT - 2 years ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 9, 2024, 4:30 PM EDT - 2 years ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Mar 20, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Nov 16, 2023, 4:01 PM EST - 2 years ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 10, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 8, 2023, 4:01 PM EST - 2 years ago

NuCana to Present at the Jefferies London Healthcare Conference

Nov 1, 2023, 4:01 PM EDT - 2 years ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Oct 16, 2023, 7:00 AM EDT - 3 years ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 3 years ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 3 years ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Aug 16, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 8:00 AM EDT - 3 years ago

NuCana to Present at the Jefferies Healthcare Conference

May 17, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 4:01 PM EDT - 3 years ago

NuCana Announces Receipt of Nasdaq Notice

Apr 14, 2023, 8:00 AM EDT - 3 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 4, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Mar 24, 2023, 4:30 PM EDT - 3 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Feb 28, 2023, 8:00 AM EST - 3 years ago

NuCana to Participate in Two Upcoming Investor Conferences

Jan 6, 2023, 4:01 PM EST - 3 years ago

NuCana Announces Receipt of NASDAQ Notice

Nov 16, 2022, 4:01 PM EST - 3 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 26, 2022, 7:00 AM EDT - 4 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Sep 12, 2022, 10:45 AM EDT - 4 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 6, 2022, 8:00 AM EDT - 4 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

ScanStock Jul. 21 at 6:21 PM

Insane run starting on ticker MLEC now! Are the low float mafia squeezing MLEC for 300% next?! Bulls shifting to MLEC. Wont be shocked to see a parabolic run 🚀🚀 $NCNA $ELAB $VCIG +

0 · Reply

bills7765 Jul. 21 at 5:01 PM

$NCNA bought 3 shares at 1.28. This is what I been doing whenever it goes down. A lot of daily buys. Makes more sense to do it this way to me.

1 · Reply

bills7765 Jul. 21 at 12:34 PM

2 · Reply

ChickenClaw Jul. 20 at 5:10 PM

$NCNA 30,000 Shares Makes It Go Up...Only 100 Shares Makes It Drop Back Down....HMMMMM

0 · Reply

ChickenClaw Jul. 20 at 5:08 PM

$NCNA Why Is This Such A Bad Stock But It Keeps Getting Large Blocks Being Bought Up?

1 · Reply

GI812 Jul. 17 at 4:59 PM

$NCNA I bought in on the early morning dip. Lowers my average and helps when we moon.

1 · Reply

ChickenClaw Jul. 17 at 2:57 PM

$NCNA

0 · Reply

Xmarketsthestock Jul. 17 at 1:44 PM

$NCNA

0 · Reply

JamoTries2Trade Jul. 17 at 8:11 AM

$NCNA scam. All bio stocks are scams. Get it through your f’ing heads already

1 · Reply

TVanda00 Jul. 15 at 8:08 PM

$NCNA Keep coming back around to…..BULLISH.

0 · Reply

bills7765 Jul. 15 at 12:34 AM

$NCNA missed enrollment completion mark. Was supposed to be done first half of year. That was june 30th. Why the slide. Should hear something soon.

1 · Reply

TradeX_ Jul. 14 at 7:46 PM

Looks like BMGL might be the next 800% runner. Crazy market! Every micro float ticker has been going parabolic this month. Would not be surprised if they send BMGL up now. BMGL starting to make its move now! Only 750k shares outstanding! 💎 Watching $NCNA $DXF nomw

0 · Reply

Flippinn_Stockz Jul. 13 at 6:46 PM

$BTAI $IPW $NCNA $SOBR $VEEE IPW💎 1.22 break confirms reversal … If it goes green we may see a VEEE type of move here folks😮‍💨😮‍💨

0 · Reply

Flippinn_Stockz Jul. 13 at 6:15 PM

$BTAI $IPW $NCNA $SOBR $VEEE IPW💎✅ next mover SOBR was exactly same chart friday! Low volume then BOOM! IPW💎 next

0 · Reply

Flippinn_Stockz Jul. 13 at 6:00 PM

$BTAI $IPW $NCNA I see a move like $SOBR and $VEEE incoming IPW💎✅

0 · Reply

GI812 Jul. 13 at 5:43 PM

$NCNA When the result's for the NUC-7738 combined with Keytruda Phase 2 expansion study are released we will know if were Golden or SOL. The company plans to release final data later in 2026 and will meet with the FDA to discuss an accelerated regulatory approval pathway.

1 · Reply

MTRADe_01 Jul. 13 at 5:42 PM

$IPW Starting a position at $1.18. A sub-$1M market cap, ~596K float, 20%+ short interest, and an RSI around 22 has my attention. This thing has been absolutely crushed, but I like the risk/reward down here. Not expecting anything overnight—just building a position where I think the odds become interesting. Bull or bear? 👇 $VRAX $BTAI $NCNA $SLS

0 · Reply

Xmarketsthestock Jul. 10 at 3:35 PM

$NCNA

0 · Reply

ChickenClaw Jul. 10 at 2:09 PM

$NCNA A Company Or Private Entity Could Pay 5 Times The Price Right Now And Break Even With Just The Cash On Hand....Then They Would Still Have All The Patents.

1 · Reply

bills7765 Jul. 10 at 1:08 AM

$NCNA this is just for sake of conversation. What are the chances a buyer comes and takes ncna private? Its at a super low amount. But the trials would be expensive. American companies dont want a cure. They want to keep u on the drugs. Does this ever happen?

2 · Reply

bills7765 Jul. 9 at 8:02 PM

$NCNA woohoo. Buy time baby!!

0 · Reply

Antoor Jul. 9 at 5:58 PM

$NCNA yeah this thing will never get back past 4 bucks ever again.

1 · Reply

Market Cap	5.47M
Revenue (ttm)	0.00
Net Income (ttm)	-38.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	15,389
Avg Vol	56,422
Day's Range	N/A - N/A
Shares Out	4.16M
Stochastic %K	36%
Beta	2.23
Analysts	Strong Buy
Price Target	$25.00